CLRM-09 FIRST-LINE Tumor TREATING FIELDS (200 KHZ) THERAPY FOR NEWLY-DIAGNOSED GLIOBLASTOMA: THE PHASE 3 TRIDENT TRIAL (EF-32)

BACKGROUND: Tumor Treating Fields therapy (TTFields; 200 kHz) comprise alternating electric fields that disrupt cancer cell division, and is approved for newly diagnosed glioblastoma (ndGBM), recurrent GBM and mesothelioma. In the phase 3 EF-14 trial, TTFields/temozolomide (TMZ) significantly increa...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Wenyin, Kleinberg, Lawrence, Jeyapalan, Suriya A, Goldlust, Samuel A, Nagpal, Seema, Roberge, David, Nishikawa, Ryo, Grossman, Rachel, Glas, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Supplement Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354170/
http://dx.doi.org/10.1093/noajnl/vdac078.029

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354170/
http://dx.doi.org/10.1093/noajnl/vdac078.029

Ejemplares similares